Natalie Mc Clure Net Worth

The estimated Net Worth of Natalie Mc Clure is at least $260 Thousand dollars as of 18 April 2016. Natalie Clure owns over 36,000 units of Adamas Pharmaceuticals Inc stock worth over $260,360 and over the last 10 years Natalie sold ADMS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Natalie Clure ADMS stock SEC Form 4 insiders trading

Natalie has made over 10 trades of the Adamas Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Natalie exercised 36,000 units of ADMS stock worth $37,800 on 18 April 2016.

The largest trade Natalie's ever made was exercising 36,000 units of Adamas Pharmaceuticals Inc stock on 18 April 2016 worth over $37,800. On average, Natalie trades about 8,154 units every 39 days since 2014. As of 18 April 2016 Natalie still owns at least 31,674 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Natalie Clure stock trades at the bottom of the page.

What's Natalie Clure's mailing address?

Natalie's mailing address filed with the SEC is 1900 Powell St #750, Emeryville, CA 94608, USA.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney, and William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Natalie Clure stock trades at Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director